Compare PNRG & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNRG | PLYX |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.2M | 271.8M |
| IPO Year | 1995 | N/A |
| Metric | PNRG | PLYX |
|---|---|---|
| Price | $176.31 | $2.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $160.00 | $10.00 |
| AVG Volume (30 Days) | 51.8K | ★ 96.3K |
| Earning Date | 04-16-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $189,052,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.18 | N/A |
| P/E Ratio | $98.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $126.40 | $2.01 |
| 52 Week High | $278.90 | $9.18 |
| Indicator | PNRG | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 41.43 |
| Support Level | $160.07 | $2.10 |
| Resistance Level | $187.50 | $2.91 |
| Average True Range (ATR) | 8.98 | 0.24 |
| MACD | 2.68 | 0.05 |
| Stochastic Oscillator | 56.72 | 16.67 |
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.